VBI-2902

{{cs1 config|name-list-style=vanc}}

{{short description|Vaccine candidate against COVID-19}}

{{Use dmy dates|date=March 2021}}

{{Infobox drug

| Verifiedfields =

| verifiedrevid =

| drug_name =

| INN =

| type = vaccine

| image =

| alt =

| caption =

| target = SARS-CoV-2

| vaccine_type = vlp

| pronounce =

| tradename =

| Drugs.com =

| MedlinePlus =

| licence_EU =

| licence_US =

| pregnancy_AU =

| pregnancy_category =

| legal_AU =

| legal_AU_comment =

| legal_BR =

| legal_BR_comment =

| legal_CA =

| legal_UK =

| legal_US =

| legal_UN =

| legal_NZ =

| legal_status =

| routes_of_administration = Intramuscular

| CAS_number = 2695526-51-1

| CAS_number_Ref = {{cite web|url=https://www.wipo.int/edocs/pubdocs/en/wipo-pub-1075-en-covid-19-related-vaccines-and-therapeutics.pdf|title=Patent Landscape Report COVID-19-related vaccines and therapeutics}}

| ATCvet =

| ATC_prefix =

| ATC_suffix =

| PubChem =

| DrugBank =

| synonyms = VBI-2902a

}}

{{COVID-19 pandemic sidebar}}

N VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.{{Cite web|last=Philippidis|first=Alex|date=2021-11-01|title=Six Up-and-Coming COVID-19 Vaccines|url=https://www.genengnews.com/topics/translational-medicine/infectious-diseases/six-up-and-coming-covid-19-vaccines/|access-date=2021-12-23|website=GEN - Genetic Engineering and Biotechnology News|language=en-US}}

History

In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".{{Cite web| title = VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902| work = VBI Vaccines| access-date = March 22, 2021| date = March 9, 2021| url = https://www.vbivaccines.com/press-releases/enrollment-in-phase-1-2-covid-study/}} VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein". By March 9, the initial Phase 1/2 study of VBI-2902 was underway.{{Cite web |title=VBI Vaccines Inc: VBI-2902a – COVID19 Vaccine Tracker |url=https://covid19.trackvaccines.org/vaccines/91/ |access-date=2022-03-27 |website=covid19.trackvaccines.org}}{{Cite journal |last=VBI Vaccines Inc. |date=2021-10-01 |title=A Phase 1a/1b, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the COVID-19 (SARS-CoV-2) Vaccine Candidates VBI-2902a and VBI-2905a in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04773665}} VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.{{Cite podcast |vauthors=Curran M, Sali D, Kovessy P |title=Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway' |url=https://obj.ca/article/local/podcast-kemptvilles-next-boom-variation-biotechnologies-56m-injection-vanier-gateway |series=Behind the Headlines |date=August 2020 |access-date=March 22, 2021 |archive-date=2 May 2021 |archive-url=https://web.archive.org/web/20210502170922/https://obj.ca/article/local/podcast-kemptvilles-next-boom-variation-biotechnologies-56m-injection-vanier-gateway |url-status=dead }}

References

{{reflist}}